🟡 60/100

Review before taking

  • Niacinamide: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacinamide: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)

This product received a low safety score because the amount of niacinamide it contains is over 14 times the recommended maximum daily limit.

Label Data

1 Tablet(s) Serving Size
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

500 mg (2500% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 14.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 500mg UL 35mg

Other Ingredients

Carnauba Wax Vegetable Stearine Magnesium Stearate Silica

Label Claims — Verification

All Other
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Sugar Free

Product Information

📋 Directions for Use

DIRECTIONS: As a dietary supplement, take one to three tablets daily with food or drink. Do not exceed recommended dose without consulting a physician.

⚠️ Warnings & Precautions

Keep out of reach of children

🧪 Formulation Notes

(CONTAINS VEGETABLE STEARINE FROM SOYBEAN OIL)

(Nicotinamide)

Contains no salt, sugar, starch, preservatives, artificial color or flavorings.

Additional Information

These tablets are specially manufactured to release the dietary ingredient continuously over a 6-8 hour period.

12502

Store at room temperature.

EP

Product Details

UPC / SKU 1 29135 12502 7
DSLD Entry Date 2013-02-25
Product Type Vitamin
Form Tablet or Pill
Brand EP
DSLD ID 17744
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →